Semaglutide (GLP-1)

The metabolic medicine community has spent two decades trying to convert GLP-1 from a clever endogenous signal into a durable drug. Semaglutide is the answer that worked, and the mechanistic insights from how it works have rewritten the textbook on appetite, satiety, and the relationship between gut hormones and the central nervous system.

Glucose-dependent insulin secretion

GLP-1 receptor activation on pancreatic β-cells potentiates insulin release in response to elevated glucose. Critically, the effect is glucose-dependent — GLP-1 does not stimulate insulin release at euglycaemia, which is why semaglutide carries far less hypoglycaemia risk than sulfonylureas or insulin itself. The same receptor activation suppresses glucagon from α-cells, addressing both sides of the insulin/glucagon balance.

Gastric emptying and the satiety cascade

Semaglutide markedly slows gastric emptying, which contributes both to lower postprandial glucose and to early-meal satiety. Combined with central appetite suppression in the arcuate nucleus of the hypothalamus and reward-circuit modulation in the dopaminergic VTA, the result is sustained reduction in food intake. This central effect is what differentiates GLP-1 agonists from older drugs that worked only peripherally.

Cardiovascular and beyond-glycaemic effects

The SELECT trial established that semaglutide reduces major adverse cardiovascular events in non-diabetic adults with obesity — a finding that goes beyond glycaemic control alone. Mechanisms include improved endothelial function, modest blood pressure reduction, reduced inflammatory markers, and direct beneficial effects on atherosclerosis. The molecule's expanding therapeutic footprint is rooted here.

The titration schedule is not optional. Starting at full therapeutic dose dramatically increases GI side effect rate and discontinuation. The 4-week step protocol — 0.25 mg, 0.5 mg, 1.0 mg, then upward if needed for obesity — is calibrated to allow GI adaptation. Users who break through tolerable nausea at one step do not need to advance; the dose-response on weight and glucose is gradual.

Metabolic stacks layer GLP-1 agonism with complementary mechanisms — amylin (cagrilintide), AMPK signalling (MOTS-c), GH-axis (tesamorelin for visceral fat) — to address dimensions of metabolic disease that GLP-1 alone does not fully cover.

• Semaglutide + Cagrilintide (CagriSema): The combination amylin + GLP-1 approach in Phase III. Cagrilintide adds central appetite suppression via amylin signalling and slows gastric emptying further. Trials show weight loss exceeding either drug alone, with similar tolerability.
• Semaglutide + Tesamorelin: For users whose body composition goal includes muscle preservation alongside fat loss. Tesamorelin's GH-axis effect targets visceral fat specifically and helps preserve lean mass during the rapid weight loss period.
• Semaglutide + MOTS-c: Layers AMPK signalling (MOTS-c) onto the GLP-1 pathway. Of interest in users with metabolic syndrome where mitochondrial function is implicated alongside the appetite-glucose axis.
• Semaglutide + BPC-157 (oral): Gut protection during the slowed-emptying phase. Useful in users prone to GI side effects or with pre-existing reflux.
• Avoid: semaglutide + sulfonylurea without dose reduction: Combined hypoglycaemia risk in diabetic users. Sulfonylurea doses should be halved or paused when initiating semaglutide.

Pancreatitis is the headline rare but serious adverse event — monitor for severe persistent abdominal pain. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2 syndrome (rodent studies show C-cell hyperplasia; relevance in humans is debated but exclusion remains standard). Pregnancy is contraindicated; discontinue at least two months before planned conception. Gallbladder events are elevated in rapid weight-loss phase. Watch for muscle mass loss; pair with resistance training in users undergoing significant weight reduction.